Body fat is usually discussed as something that should be reduced. Excess fat, particularly around the internal organs and liver, is strongly associated with insulin resistance and type 2 diabetes. However, new research highlights an important biological paradox: losing healthy fat tissue can also cause severe metabolic disease.
The key distinction is between ordinary weight loss and pathological fat loss. Healthy weight reduction generally lowers diabetes risk in people with overweight or obesity. The new findings concern lipodystrophy, a group of rare disorders in which functional fat cells become damaged, disappear or develop in an abnormal pattern.
Researchers studying familial partial lipodystrophy type 2 found that affected fat cells lose their ability to process and store lipids, develop mitochondrial problems and enter an inflammatory state. As the tissue deteriorates, fat can no longer be stored safely beneath the skin and may instead accumulate in organs such as the liver. The resulting metabolic disruption can contribute to severe insulin resistance, fatty liver disease and diabetes.
The “Wrong Fat” Is Healthy Storage Tissue
The phrase “losing the wrong fat” does not mean that intentional weight loss through a balanced diet, exercise or prescribed obesity treatment causes diabetes.
The National Institute of Diabetes and Digestive and Kidney Diseases states that losing approximately five to seven percent of starting body weight can help people at elevated risk prevent or delay type 2 diabetes. Weight reduction can also improve glucose control in people who already have the condition.
The harmful loss described in the new research involves subcutaneous adipose tissue, the functional fat stored beneath the skin. This tissue acts as a controlled storage system for excess energy. It absorbs fatty acids after meals, releases them when energy is needed and produces hormones that help regulate appetite, insulin sensitivity and metabolism.
When healthy subcutaneous tissue disappears, the body does not necessarily stop receiving or producing fat. It simply loses an appropriate place to store it.
The condition examined by the researchers, familial partial lipodystrophy type 2, commonly causes progressive fat loss from the arms, legs and trunk beginning around puberty. At the same time, fat may accumulate around the neck, face or abdomen. Many affected people develop diabetes during early or middle adulthood despite appearing lean or muscular in their limbs.
Fat Tissue Is an Active Metabolic Organ
Fat cells were once viewed mainly as passive containers for surplus calories. Scientists now understand that adipose tissue behaves more like an endocrine organ.
Healthy adipocytes store triglycerides and prevent excessive amounts of fat from circulating through the bloodstream. They also release hormones, including leptin and adiponectin, that influence appetite, energy balance and the way tissues respond to insulin.
Adiponectin generally supports insulin sensitivity and healthy fatty-acid metabolism. Leptin communicates information about the body’s energy stores to the brain and helps coordinate appetite and metabolism.
The new Journal of Clinical Investigation study found that people with established familial partial lipodystrophy type 2 had lower circulating leptin and adiponectin levels. They also showed higher glycated haemoglobin, triglycerides, non-esterified fatty acids and glucose responses than unaffected participants.
This helps explain why the complete absence of healthy fat is not metabolically desirable. The body needs functioning adipose tissue, but it also needs that tissue to remain capable of expanding, storing lipids and communicating with other organs.
Researchers Studied Families and a New Mouse Model
The study involved eight families containing people with developing or established familial partial lipodystrophy type 2. Researchers analysed clinical measurements and biopsies taken from subcutaneous fat in different body regions.
They used bulk and single-nucleus RNA sequencing to examine how gene activity differed between affected and unaffected tissue. The analysis identified reduced activity in pathways involved in fatty-acid metabolism, mitochondrial function and protein production. At the same time, genes connected with inflammation, immune-cell recruitment and tissue remodelling became more active.
The researchers also developed a mouse model in which the Lmna gene could be switched off specifically inside mature fat cells. Pathogenic variants in the human version of this gene, LMNA, cause familial partial lipodystrophy type 2.
LMNA produces lamin A and lamin C, proteins that help support the cell nucleus and influence gene regulation. When the researchers removed these proteins from mouse adipocytes, the cells progressively shrank and disappeared. The changes resembled the abnormalities observed in human tissue, strengthening the connection between LMNA dysfunction and fat-cell failure.
The study was not a weight-loss trial, and it did not show that reducing body fat through ordinary lifestyle changes produces the same effect. It investigated a rare inherited disease involving abnormal fat-cell biology.
Damaged Fat Cells Lose Their Storage Ability
A healthy adipocyte must be able to absorb fatty acids, convert them into stored triglycerides and release them safely when the body needs energy.
The researchers found that LMNA-deficient adipocytes lost activity in many of the pathways required for this work. Mitochondrial pathways were also suppressed. Because mitochondria provide energy and support cellular metabolism, their dysfunction can make it increasingly difficult for a fat cell to survive.
Inflammation added another layer of damage. Immune cells within the tissue shifted toward inflammatory programmes, while the surrounding extracellular structure showed signs of fibrosis and remodelling. Instead of behaving like flexible, metabolically active storage tissue, the fat depot became stressed and unhealthy.
The findings suggest that fat loss in familial partial lipodystrophy is not simply caused by adipocytes becoming empty. The cells experience a combination of impaired lipid metabolism, mitochondrial dysfunction, inflammation and structural stress before eventually disappearing.
Fat Then Accumulates in the Wrong Places
When subcutaneous adipose tissue cannot store incoming energy, lipids can remain elevated in the bloodstream or accumulate in tissues not designed for long-term fat storage.
This is known as ectopic fat deposition. It can affect the liver, skeletal muscles and other organs. Fat inside the liver is particularly common in lipodystrophy and can contribute to metabolic dysfunction and progressive liver disease.
Excess lipid exposure can interfere with insulin signalling. Muscle cells may stop responding normally to insulin, while the liver may continue releasing glucose even when blood sugar is already elevated. The pancreas then produces more insulin in an attempt to compensate.
Over time, the insulin-producing beta cells may no longer keep up with the increased demand. Blood glucose rises, and diabetes develops.
The NCBI Endotext overview of lipodystrophy describes these conditions as lipid-partitioning disorders. The central problem is a shortage of functional adipocytes, followed by ectopic fat, severe dyslipidaemia and insulin resistance.
This explains why obesity and lipodystrophy can produce surprisingly similar metabolic consequences. In obesity, existing fat tissue may become overfilled and dysfunctional. In lipodystrophy, there may be too little healthy tissue to store energy in the first place. Both situations can cause lipids to overflow into other organs.
Why Some Lean People Develop Severe Diabetes
Body mass index cannot reveal how well a person’s fat tissue is functioning or where fat is being stored.
Someone with familial partial lipodystrophy may have little visible fat on the arms and legs but substantial fat around the abdomen, liver or neck. Prominent muscles can develop because the layer of subcutaneous fat covering them has disappeared, not because the person has unusually low metabolic risk.
Clinical signs can include progressive loss of fat from the limbs or buttocks, unusual muscular definition, accumulation around the face or neck, darkened skin associated with insulin resistance, very high triglycerides, fatty liver disease and diabetes that is difficult to control.
The condition is rare and can be mistaken for ordinary central obesity, Cushing-like body changes or type 2 diabetes in a lean person. Imaging methods such as MRI or dual-energy X-ray absorptiometry may help define fat distribution, while genetic testing can identify some inherited forms.
The Discovery Could Point to New Treatments
Current management focuses largely on the consequences of lipodystrophy, including diabetes, high triglycerides and liver disease. Treatment must be individualised and usually requires specialist endocrinology care.
Metreleptin, a laboratory-produced form of leptin, is approved in the United States as an addition to diet for complications of leptin deficiency in congenital or acquired generalised lipodystrophy. Its approved indication does not currently cover ordinary obesity, and its effectiveness for partial lipodystrophy has not been established in the US product label. The exact indication can be reviewed in the FDA’s Myalept prescribing information.
The new research raises a different therapeutic possibility: protecting adipocytes before they deteriorate. Treatments that preserve mitochondrial activity, maintain lipid-processing pathways or reduce harmful inflammation might help retain functioning fat tissue and prevent metabolic complications.
Those possibilities remain research goals rather than available treatments. The study identified mechanisms and potential targets but did not test a new therapy in patients.
Healthy Fat Loss and Pathological Fat Loss Are Not the Same
The most important conclusion is not that body fat should be preserved at all costs. Excess visceral and liver fat remain major contributors to insulin resistance, and medically appropriate weight loss continues to be one of the most effective strategies for preventing and managing type 2 diabetes.
The discovery shows that fat quality, function and location matter alongside total quantity.
Losing excess fat through healthy weight management can reduce metabolic pressure. Losing functional adipocytes through a genetic or acquired lipodystrophy disorder removes the body’s safe energy-storage system. The same word—fat loss—therefore describes two biologically different processes with very different health effects.
The findings broaden the understanding of diabetes beyond the pancreas and insulin-producing beta cells. Diabetes can also begin when fat cells fail to perform their normal job, allowing lipids to accumulate where they become harmful.
